Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Parestat(generic parecoxib)

Phase 3Small molecule

UUniversity of Malaya

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast SurgeryNot yet recruiting

Breast SurgeryPhase 3

Not yet recruiting

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

Breast Surgery

NCT07154446

Clinical

Trials by Indication[1]

Breast Surgery1 trial

Study Comparing Dynastat and Parestat Pain Relief Medications for Patients After Breast Surgery

Not yet recruiting·UUniversity of Malaya·Phase 4·NCT07154446·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Parestat(generic parecoxib). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Parestat(generic parecoxib) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Parestat(generic parecoxib). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Malaya company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Malaya

Related News